Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
-
Narrated by:
-
By:
About this listen
Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.
This programme is made possible thanks to an independent educational grant from AstraZeneca.
Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
adbl_web_global_use_to_activate_webcro805_stickypopup
No reviews yet